We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » German Watchdog Finds No Benefit for Bayer’s Eylea over Lucentis
German Watchdog Finds No Benefit for Bayer’s Eylea over Lucentis
A German healthcare watchdog questioned the efficacy of Bayer’s Eylea for a third time, which could affect the reimbursement price of the profitable eye drug.